AKBA

Dopo l'orario di chiusura: 1.45 -0.01 -0.68%

Akebia Therapeutics Inc (AKBA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Akebia Therapeutics Inc

Healthcare (1116)

617-871-2098

245 FIRST STREET, CAMBRIDGE, MA

Prossima data di guadagno

Ultimi documenti SEC

AKBA's Discussions on Twitter

Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AKBA Akebia Therapeutics Inc	1.46	391.10M	194.75M	-51.26M	-23.38M	-0.28
TAK Takeda Pharmaceutical Co Adr	17.77	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.62	48.81B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.03	44.67B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.57	33.27B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	536.12	23.50B	3.18B	1.33B	1.04B	27.90

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-04	Ripresa	H.C. Wainwright	Buy
2025-04-28	Iniziato	Leerink Partners	Outperform
2025-04-01	Iniziato	Jefferies	Buy
2023-11-29	Ripresa	BTIG Research	Buy
2023-08-28	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-05-31	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-03-31	Downgrade	H.C. Wainwright	Buy → Neutral
2022-03-31	Downgrade	Mizuho	Buy → Neutral
2022-03-31	Downgrade	Needham	Buy → Hold
2022-03-31	Downgrade	Piper Sandler	Overweight → Neutral
2021-03-08	Iniziato	Cantor Fitzgerald	Overweight
2021-01-29	Downgrade	JP Morgan	Neutral → Underweight
2019-11-14	Reiterato	Needham	Buy
2019-08-06	Reiterato	H.C. Wainwright	Buy
2019-07-11	Reiterato	H.C. Wainwright	Buy
2019-05-02	Iniziato	JP Morgan	Overweight
2019-03-20	Iniziato	Citigroup	Neutral
2018-09-07	Ripresa	Morgan Stanley	Equal-Weight
2018-08-10	Reiterato	Needham	Buy
2018-06-06	Reiterato	H.C. Wainwright	Buy
2017-12-19	Iniziato	Piper Jaffray	Overweight
2017-12-07	Iniziato	BTIG Research	Buy
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-07-10	Reiterato	H.C. Wainwright	Buy
2017-04-27	Reiterato	H.C. Wainwright	Buy
2017-04-27	Reiterato	Needham	Buy
2016-12-27	Reiterato	H.C. Wainwright	Buy
2016-12-20	Reiterato	JMP Securities	Mkt Outperform
2016-11-15	Iniziato	Aegis Capital	Buy
2016-09-29	Iniziato	Brean Capital	Buy
2016-03-16	Reiterato	Needham	Buy
2016-01-21	Iniziato	Credit Suisse	Neutral

Mostra tutto

Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie

Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari

Akebia Therapeutics Inc (AKBA)

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie

Akebia Q2 2025 Earnings Preview - MSN

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference - Yahoo Finance

Akebia Therapeutics Earnings Call: Vafseo Drives Growth - The Globe and Mail

Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline By Investing.com - Investing.com Canada

How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset - finance.yahoo.com

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - MSN

Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares - MarketBeat

Layoff Watch: Does Akebia Therapeutics Inc offer margin of safety2025 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat

Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - The Globe and Mail

Akebia Therapeutics CEO to speak at Miami Leerink 2026 healthcare forum - Stock Titan

Akebia Therapeutics Reports Inducement Grants - National Today

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail

Akebia Therapeutics (NASDAQ:AKBA) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat

Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A Potential 233% Upside in the Healthcare Sector - DirectorsTalk Interviews

Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript - Insider Monkey

Akebia Therapeutics (AKBA) Loss In Q4 2025 Tests Bullish Margin Narratives - simplywall.st

Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus

Akebia Therapeutics, Inc. posts full year 2025 financial results amid commercial and pipeline expansion - Traders Union

Key facts: Akebia Therapeutics reports 47% revenue rise; Phase 2 trials planned - TradingView

Akebia (AKBA) Q4 2025 Earnings Call Transcript - AOL.com

Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat

Akebia Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI

Akebia Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

AKBA: Vafseo launch drove 50% revenue growth in 2025, with expanding adoption and robust cash reserves - TradingView

Akebia Therapeutics Q4 Earnings Call Highlights - MarketBeat

Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction - ChartMill

Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus

AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative

Akebia Therapeutics, Inc. Q4 Loss Decreases - Nasdaq

Akebia Therapeutics, Inc. SEC 10-K Report - TradingView

AKBA: Revenue surged 47% to $236.2M in 2025, with Vafseo launch and pipeline expansion offsetting Auryxia LoE - TradingView

Akebia Therapeutics: Q4 Earnings Snapshot - Barchart

[8-K] Akebia Therapeutics, Inc. Reports Material Event | AKBA SEC FilingForm 8-K - Stock Titan

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - The Manila Times

AKBA: Strong 2025 revenue growth and improved margins set the stage for Vafseo-led expansion in 2026 - TradingView

Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail

Uncovering Potential: Akebia Therapeutics's Earnings Preview - Benzinga

BTIG Research Has Lowered Expectations for Akebia Therapeutics (NASDAQ:AKBA) Stock Price - MarketBeat

Where Akebia Therapeutics Stands With Analysts - Benzinga

BTIG Maintains Buy Rating on AKBA, Lowers Price Target by 20% | AKBA Stock News - GuruFocus

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Akebia Therapeutics, Inc. (AKBA): Investor Outlook Reveals 289.83% Potential Upside - DirectorsTalk Interviews

Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AKBA